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ABSTRACT
Coccidioidomycosis is a fungal disease endemic to the southwestern USA, northern 
Mexico, and focal areas in Central and South America, but it is rarely reported in 
Taiwan. We report a case of coccidioidomycosis of probable pulmonary origin in a 
young woman, who came back to Taiwan after a 10-month stay in the Central Valley of 
California. Coccidioidomycosis was suspected by typical constellation of symptoms 
and signs of Valley fever and subsequent desert rheumatism. The diagnosis was con-
firmed by positive results of latex agglutination, immunodiffusion tube precipitation 
and immunodiffusion complement fixation tests. We prescribed symptomatic treatment 
without any anti-fungal agent according to the Infectious Disease Society of America 
guidelines, and the clinical symptoms and signs gradually subsided 3 weeks later.
Although coccidioidomycosis is rare in Taiwan, it is believed that the real incidence 
has been underestimated. Clinicians must be familiar with the typical manifestations 
and consider the diagnosis of coccidioidomycosis when an individual presents with 
fever, cough, arthralgia and skin eruptions such as erythema nodosum and/or erythema 
multiforme with a traveling history to the endemic area.
Copyright © 2010, Taiwanese Dermatological Association. 
Published by Elsevier Taiwan LLC. All rights reserved.
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Introduction
Coccidioidomycosis (San Joaquin fever, Valley fever) is a 
fungal disease found mostly in the Western hemisphere.1 It is 
caused by two nearly identical fungal species, Coccidioides 
immitis, and C. posadasii. Endemic regions include south-
western USA with California (mainly San Joaquin Valley), 
western Texas, New Mexico and the desert areas of Arizona, 
and Central and South America. Many tourists and visitors 
acquire the infection. The classic symptoms of Valley fever 
include fever, cough, shortness of breath, pleuritic chest pain, 
fatigue, weight loss and headaches, and it may be followed by 
a triad of desert rheumatism (fever, erythema nodosum, and 
arthralgia). We report a case of coccidioidomycosis and it 
was confirmed by latex agglutination (LA), immunodiffusion 
tube precipitation (IDTP) and immunodiffusion complement 
fixation (IDCF) tests in Taiwan.
Case report
A 29-year-old female Taiwanese copilot had been in the 
Central Valley of California for flight training since July 
2008. Generalized malaise, dry cough, night sweating, and 
mild fever, appeared half a month before she came back to 
Taiwan. Intermittent headaches, generalized nonitchy mac-
ulopapules, hemorrhagic vesicles within the lip and buccal 
mucosa and tender swelling over the left ankle were also 
found. The lesions subsided without treatment. She returned 
to Taiwan on 2 May, 2009; tender erythematous nodules 
over bilateral lower extremities, which progressed to her 
upper extremities, and aggravation of the left ankle swelling 
(Figure 1) were found.
The patient came to our emergent department because of 
fever and progressive tender skin lesions on 19 May, 2009. 
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A physical examination showed mild fever (37.6°C) and tachy-
cardia. Fine bilateral basilar crackles and painless, movable, 
lymphadenopathy at the right of the base of the neck were 
also discovered. No photophobia, conjunctivitis, maculo-
papules, oral lesions, or abdominal discomfort were found. 
A chest radiograph at our emergent department revealed 
mild exaggerated lung markings and a suspicious cavitating 
lesion at the right upper lobe (Figure 2). A lab examination 
showed leukocytosis with a white blood cell count of 
11.2 × 109/L (normal range: 3.9 × 109–10.6 × 109/L), atypical 
lymphocytes were 3.0% and the erythrocyte sedimentation 
rate was elevated (66 mm/hr) (normal range: 1–20 mm/hr). 
A basic metabolic panel showed elevation of C-reactive pro-
tein levels (1169 nmol/L) (< 47.6 nmol/L), but there were no 
remarkable findings for a liver function test, serum creatinine, 
antinuclear antibody, C3 and RPR-VPRL (Rapid Plasma Reagin-
Venereal Disease Research Laboratory). Urinary analysis 
showed no pyuria. Blood cultures for bacteria and fungi 
were collected and showed negative results. Sputum cul-
ture was not available because of scanty sputum and the 
patient refused bronchoalveolar lavage. A skin biopsy was 
performed. Histopathology of the skin specimen showed 
septal fibrosis and thickened vessels with mononuclear 
cells in fat lobules. Focal granulomatous inflammation with 
occasional multinucleated giant cells was also observed 
but no remarkable pathogens were found (Figure 3). These 
findings were consistent with erythema nodosum. We also 
contacted the Taiwan Centers for Disease Control to submit 
the patient’s serum for LA, IDTP and IDCF because of a 
high suspicion of coccidioidomycosis. The results of LA 
(not shown), IDTP and IDCF were all positive (Figure 4) and 
the diagnosis of coccidioidomycosis was confirmed.
We did not administer antifungal agents because there 
was no evidence of systemic spread and clinically evanes-
cent disease course. However, we gave symptomatic medi-
cation and scheduled regular outpatient visits every 3 months 
for 1 − 2 years according to the Infectious Disease Society of 
America guidelines for uncomplicated primary pulmonary 
infection.
Three weeks later, follow-up chest radiography (Figure 5) 
and computed tomography (Figure 6) showed that the previ-
ous cavitating lesion observed on a chest radiograph over the 
right upper lobe had eventuated into a pulmonary nodule. 
Computed tomography revealed multiple reactive lymphad-
enopathy within bilateral lung fields and the mediastinum. 
Erythema nodosum had improved with remnant dull-brownish 
patches. Follow-up laboratory tests showed no leukocytosis 
and normal C-reactive protein levels. No other noteworthy 
symptoms and signs were found.
Discussion
Coccidioidomycosis is a fungal infection acquired by inhala-
tion of arthroconidia in the arid desert soil in southwestern 
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Figure 1 Erythema nodosum-like lesions over (A) bi-
lateral lower extremities and (B) the left upper arm. 
(C) Erythematous tender swelling over the left ankle.
R
Figure 2 Chest radiograph at the emergency department. The arrow-
head indicates a cavitating lesion over the right upper lobe.
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USA, northern Mexico and several areas of South America.1 
Only two cases have been reported in Taiwan. One case devel-
oped disseminated macules on the trunk and four limbs with 
pulmonary and lymph node involement,2 and the other died 
from fulminant disseminated coccidioidomycosis without 
cutaneous manifestation.3 Our case presented with cutaneous 
erythema nodosum, arthralgia, and mild pulmonary symp-
toms, which suggested the diagnosis of coccidioidomycosis.
The fungus grows in a hardy mycelial phase in the soil 
and can remain viable for months to years. As the soil dries 
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Figure 3 (A) Prominent septal fibrosis and thickened vessels with mononuclear cells in fat lobules (H&E, 40×). (B) Focal granulomatous inflammation 
with occasional multinucleated giant cells is seen but there are no spherules (H&E, 200×).
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Figure 4 Results of (A) immunodiffusion tube precipitation (IDTP) and (B) immunodiffusion complement fixation (IDCF). White arrows indicate 
positive results (immune complex deposition). The two wells of each sample represent duplicate tests.
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Figure 5 Chest radiograph 3 weeks later. The arrow indicates the pre-
vious cavitating lesion that eventuated into a nodule.
Figure 6 Computed tomography 3 weeks later reveals a nodule in 
the superior segment of the right lower lobe and other tiny nodules in 
both lungs.
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or nutrients become limiting, the fungus rapidly reproduces 
asexually by disarticulating the hyphae into small, environ-
mentally resistant arthroconidia (reproductive spores) after 
rain. Wind disperses these arthroconidia into the air and 
they are inhaled by animals or humans.4 Within the lung, 
one arthroconidia is able to transform into new, multinucle-
ated spherules, which vary in size from 10 μm to 80 μm, with 
the average size being approximately 40 μm containing 800–
1000 endospores (2–5μm), and each endospore grows into 
a new spherule that causes the disease.5
Coccidioidomycosis is seldom contagious in the spherule 
phase. Human-to-human spread is extremely rare. Primary 
exposure to contaminated soil or dust is the only risk factor 
for the acquisition of this disease. Of infected individuals, 
60% are asymptomatic and the remaining 40% manifest as 
self-limited “influenza-like” symptoms after 7–21 days of 
inhalation of arthroconidia,4 and 0.5–1.5% develop dissemi-
nation to the skin, bones, joints, or central nervous system.6 
Disseminated coccidioidomycosis most frequently occurs 
in African Americans, Filipinos, Hispanics, and Native 
Americans, the elderly, pregnant women, and those with 
cellular immunodeficiencies.7,8
The cutaneous manifestations of C. immitis are different 
between acute pulmonary coccidioidal exanthem, the primary 
cutaneous form and the secondary cutaneous form. During 
the acute pulmonary coccidioidal exanthem, toxic erythema, 
erythema nodosum, and/or erythema multiforme are mostly 
encountered. These are classified as reactive or nonspecific 
manifestations in which no detectable organisms are found 
on biopsy4 as in our case. A generalized toxic erythema occurs 
in 12% of patients with symptomatic pulmonary coccidioi-
domycosis.8 Both erythema nodosum and erythema multi-
forme are more commonly found in females and they are 
associated with a favorable prognosis (disseminated disease 
is unlikely).6
In the present case, symptoms of Valley fever such as fever, 
cough, equivocal pleuritic chest pain, fatigue and severe 
headaches with toxic erythema were initially noted, as well 
as influenza-like symptoms and prominent left ankle arthral-
gia. Erythema nodosum was then found over the patient’s four 
limbs. Skin biopsy of the erythema nodosum-like lesion re-
vealed no pathogens within the tissue and this represented 
a reactive process. Furthermore, this was then followed by 
the triad of fever, erythema nodosum, and arthralgia, also 
known as desert rheumatism. The arthralgia seemed to be a 
reactive process. However, the presence of pathogens in 
the tissue remains to be elucidated.
Although it is extremely rare, C. immitis may directly in-
volve the skin by primary puncture of the organism into the 
skin after an inoculation period of 2–3 weeks (primary cu-
taneous coccidioidomycosis) resulting in a protean mani-
festation such as papules, nonhealing chancriform ulcers, 
verrucous nodules or granulomatous plaques with local 
lymphadenopathy.9 More commonly, the skin is involved 
as a secondary locus after systemic dissemination (second-
ary cutaneous coccidioidomycosis) a few months after a 
primary pulmonary infection.10
Disseminated coccidioidomycosis may be initially difficult 
to identify, as it is also a great imitator of other diseases11 
and secondary cutaneous involvement may occur without 
historical, physical, or radiographic evidence of prior or co-
existing infection.5 Dissemination of coccidioidomycosis to 
the skin may also mimic other diseases including contact der-
matitis, tuberculosis, leprosy, sarcoid, acne, basal or squa-
mous cell carcinoma, scars, warts and lupus vulgaris.6,7,10–13
Infections of coccidioidomycosis should be considered 
in persons who reside or have traveled from endemic areas 
and present with upper respiratory tract symptoms, arthral-
gia and skin eruptions. Diagnosis of coccidioidomycosis 
depends on direct histological identification of the fungus 
in tissue or respiratory secretions, culture, or serology.14
Tissue specimens stained with hematoxylin and eosin, 
periodic acid-Schiff, or Grocott-methenamine silver stain 
will all show the organism, although silver stain is consid-
ered the most sensitive method.4 The histopathology may 
show granulomas, abscess formation with necrosis, and/or 
vascular proliferation and inflammatory cell reactions, which 
may resemble vasculitis.10 In addition, fungal cultures are 
helpful in confirming the diagnosis. Laboratory personnel, 
however, should be informed when cultures are submitted, 
as C. immitis is a laboratory biohazard.6
Serologic testing is most frequently used to identify coc-
cidioidal infections. Most of the available tests are highly 
specific for an active infectious process. However, a nega-
tive result does not exclude a coccidioidal infection.4
The LA test is a sensitive and rapid screening test (sen-
sitivity: 66%, specificity: 93%), but it has at least a 6% 
false-positive rate.15 Although tube precipitation and com-
plement fixation assays are traditional methods, few labo-
ratories currently perform these assays.14 IDTP and IDCF 
tests are simplified qualitative analyses at least as sensitive 
as their original counterparts.15 Since the LA test is not as 
specific as the IDTP test and a false-positive rate remains, 
confirmation of results of LA by immunodiffusion is recom-
mended.15 No single test is adequate for detecting all posi-
tive coccidioidal specimens. The LA, IDTP and IDCF tests 
performed simultaneously can detect 93% of coccidioido-
mycosis cases.15
Treatment of coccidioidomycosis (Table 116) initially in-
volves recognizing a coccidioidal infection, defining the 
extent of infection, and identifying host factors that predis-
pose to disease severity, i.e. AIDS, high dose glucocorticoid 
administration, diabetes mellitus, pregnancy, and antitu-
mor necrosis factor therapy. Patients with localized acute 
pulmonary infections and no risk factors for complications 
often require only periodic reassessment to demonstrate 
resolution of their self-limited process. Nevertheless, pa-
tients with extensive involvement or who are at high risk of 
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Table 1 Clinical presentation of coccidioidomycosis, their frequency, and recommended initial therapy for the immunocompetent host.
Clinical presentation Frequency, % Recommended therapy
Asymptomatic 60 None
Primary pneumonia (focal) 40 In most cases, none*
Diffuse pneumonia  < 1 Amphotericin B followed by prolonged oral triazole therapy
Pulmonary sequelae  5
 Nodule – None
 Cavity – In most cases, none†
 Chronic pneumonia – Prolonged triazole therapy
Disseminated disease  ≤ 1
 Skin, bone, joint, soft tissue – Prolonged triazole therapy‡
 Meningitis – Life-long triazole therapy§
*Treatment is indicated for hosts with depressed cellular immunity as well as for those with prolonged symptoms and signs of increased severity, includ-
ing night sweats for > 3 weeks, weight loss of > 10%, a complement-fixation titer of > 16, and extensive pulmonary involvement on chest radiography; 
†treatment (usually the oral triazoles fluconazole and itraconazole) is recommended for persistent symptoms; ‡in severe cases, some clinicians use ampho-
tericin B as the initial therapy; §intraventricular or intrathecal amphotericin B is recommended in cases of triazole failure. Hydrocephalus may occur, 
requiring a cerebrospinal fluid shunt.
complications because of immunosuppression or other 
preexisting factors require a variety of therapeutic strategies 
that may include antifungal agents, surgical debridement, 
or a combination of both. Azole antifungals, primarily flu-
conazole and itraconazole, have replaced amphotericin B 
as the initial therapy for most chronic pulmonary or dissem-
inated infections. Amphotericin B is now reserved for pa-
tients with respiratory failure due to coccidioidal infection, 
those with rapidly progressive coccidioidal infections, or 
women during pregnancy. Therapy often ranges from months 
to years in duration, and in some patients, lifelong suppressive 
therapy is needed to prevent relapses.17
Although coccidioidomycosis is an endemic disease 
chiefly of the western hemisphere, and one which rarely 
occurs in Taiwan, it should be considered whenever there is 
a differential diagnosis of pneumonia resistant to standard 
medication with small cavitating and/or nodular lesions on a 
chest radiograph associated with variable skin manifestations 
such as erythema nodosum and arthralgia, as well as ar-
thralgia and/or arthritis. Inquiring into the traveling history 
to endemic areas plays a pivotal role in the correct diagno-
sis of the disease. If there are any problems detecting the 
infection in an individual, the patient’s serum and probable 
sputum or other tissue fluid can be submitted to the Taiwan 
Centers for Disease Control. Treatment is not routinely neces-
sary because most infections are self-limited and the thera-
peutic protocol must be individualized according to the 
Infectious Disease Society of America guidelines.
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